What is CRISPR-CAS 9?
The CRISPR-CAS 9 system is a unique tool that allows scientists to make precise, targeted changes to the genome by deleting, replacing or inserting parts to specific locations in the DNA sequence.
CRISPR-CAS 9 cuts time in half for genome sequencing and is more effective for researchers analyzing genomes, RNA, and proteins of various diseases. CRISPR-CAS 9 also offers great hope certainly for the rare disease patient community, especially as it relates to future immunotherapy breakthroughs for LMS.
KNOWLEDGE IS POWER – BE EMPOWERED!
How It Works:
The Targeted Agent and Profiling Utilization Registry (TAPUR) study is a clinical trial for people with advanced cancer whose cancer is no longer responding to standard treatment or for whom there is no standard treatment available.
A patient’s cancer must also have a potentially actionable genomic variant already identified through a genomic test –talk to your oncologist about this for more information about participating in a TAPUR study and the genomic testing step.
The TAPUR study aims to:
- learn whether approved drugs might work against different cancers
- find out how genomic or molecular tests are used to care for people with advanced cancer
- use the study results to help inform future studies and aid in the care of people with cancer
- provide patients with access to therapies which may benefit them
The TAPUR STUDY website will have information about the eligibility of the study; latest news and study announcements, the list of drugs available in the study, and a current listing of study sites in the country.